This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • AveXis/Novartis receives EC approval and activates...
News

AveXis/Novartis receives EC approval and activates “Day One” access program for Zolgensma, the only gene therapy for spinal muscular atrophy (SMA).

Read time: 3 mins
Last updated:20th May 2020
Published:20th May 2020
Condition: Spinal Muscular Atrophy
Type: drug
Register now for full access to medthority.com